Oral Health Considerations for Patients With Systemic Disease
Introduction
Dental procedures may appear routine, but they often involve irreversible surgical interventions to hard and soft oral tissues, underscoring the inherently invasive nature of general dental practice. Although these procedures are typically less physically traumatic compared to many medical surgeries, they still carry potential for systemic consequences.[1] A combination of aging population demographics, people retaining teeth for longer and later in life, and an increase in health conditions that can be surgically or medically managed results in a growing population requiring dental care in the background of systemic disease. The increasing prevalence and incidence of systemic diseases increases the need for a comprehensive risk assessment before proceeding with many dental treatments. Although there are very few outright medical contraindications to receiving dental care, certain factors may increase the risk of poor outcomes, including morbidity and mortality.[2]
Function
Register For Free And Read The Full Article
Search engine and full access to all medical articles
10 free questions in your specialty
Free CME/CE Activities
Free daily question in your email
Save favorite articles to your dashboard
Emails offering discounts
Learn more about a Subscription to StatPearls Point-of-Care
Function
Providing safe and effective dental care for patients with systemic disease is a stepwise process. The process begins with a comprehensive evaluation of the patient, based on their age, medical history, and physical, cognitive, emotional, and functional status. These factors should be evaluated in conjunction with treatment factors, such as the drugs administered, level of consciousness, invasiveness, and duration of the procedure, to ensure consistent quality care. This diagnostic framework relies on the acquisition of high-quality historical, clinical, physiological, biological, and imaging information, as well as effective communication among healthcare providers across multiple domains.
Issues of Concern
Unfortunately, there exists an artificial separation of oral health and overall health in most healthcare systems. Although several measures have been implemented to better integrate oral health into overall health, including the United States Surgeon General's report in 2000 [3] and the World Health Organization's report in 2021,[4] this separation persists.[5] As a result, there is a separation of teaching of oral and general health, often a separation of electronic health records between the dental and medical teams, and barriers to sharing information, communication, and understanding. Accordingly, patients may not understand why a dentist needs to know about their personal medical history, their medications, and their medical status. In turn, clinicians may not fully understand the intricacies and risks associated with dental care. These factors can contribute to misunderstandings and miscommunications, which can lead to sub-optimal clinical decision-making.
Ensuring optimal oral health for individuals is a critical component of overall health.[6][7] Recommendations for a comprehensive oral examination before certain treatments include those involving chemotherapy, radiation therapy, renal replacement therapy, or major surgery.[8][9][10][11] The latter 2 procedures are both services covered under Centers for Medicare and Medicaid Services since 1979, with the following rationale—an oral examination… is for the identification, before a complex surgical procedure, of existing medical problems where the increased possibility of infection would not only reduce the chances for successful surgery but would also expose the patient to additional risks in undergoing such surgery. However, these recommendations are not routinely applied in all medical facilities.
Clinical Significance
The prevalence of systemic disease among dental patients ranges from approximately 12% to 35%, depending on the population and care setting, with higher rates in public health systems and among older adults. For example, in a large university dental clinic, 12% of patients had a medically compromised condition, with the most common being allergies, hypertension, diabetes mellitus, heart disease, and thyroid disease. In another study, the prevalence of systemic disease was 35% in public dental patients and 28% in private practice, with higher rates in those younger than 65 for rheumatic and endocrine-metabolic disorders.[12]
Assessing a patient's medical status can be a complex process. To facilitate this, workflow diagnostic systems have been developed as methods for collating and evaluating various factors when planning dental treatment for patients. Below are some of the more common systems currently utilized.
- The American Society of Anesthesiologists' physical status classification has long been used as a method for stratifying the potential for unwanted outcomes (primarily mortality) associated with dental care in medically complex individuals.[Meyer Saklad; GRADING OF PATIENTS FOR SURGICAL PROCEDURES. Anesthesiology. 1941; 2:281-284. doi: https://doi.org/10.1097/00000542-194105000-00004] However, its primary design was to assess risk during general anesthesia, not dental procedures, so its use as a risk assessment system for dental treatment and management is limited.
- The Charlson Comorbidity Index [13] was developed as a method of analyzing 1-year mortality in patients with breast cancer who also had comorbid conditions. Comorbid conditions are assigned a weighting score, allowing for the assessment of the effects of multiple comorbid conditions on 1-year mortality. The Charlson Comorbidity Index has been used to analyze and evaluate in-hospital mortality.[14] The Medical Complexity Score is similar to the American Society of Anesthesiologists' physical status. This score has been used as a more specific method for assessing risks associated with patients requiring dental treatment or management.[Michael Glick et al. Burket's Oral Medicine, 13th edition. Wiley-Blackwell; 2021] Major categories evaluate the status of medical conditions. The subcategories outline anticipated complications associated with dental care and the recommended setting for addressing these complications.
- The World Health Organization's International Classification of Functioning, Disability and Health (ICF) has long been used as an effective method of assessing patients' activities and abilities across multiple domains. This model offers a more holistic approach to evaluating patients and their potential needs associated with all forms of care, including dental care.[World Health Organization. International Classification of Functioning, Disability and Health (ICF)]
Regardless of the method or system used for patient assessment, it represents only part of a more comprehensive process. Other components of successful dental management include the healthcare provider's or team's skills, abilities, and compassion in providing the proposed care and supporting patients after treatment.
Key factors to consider when assessing dental patients include:
- Demographics and social determinants of health
- Preexisting burden of disease, disease risk factors, and behaviors
- Cognitive capacity and ability to communicate
- Emotional responses within the dental environment
- Functional capacity and co-morbidities
When planning treatment for patients with systemic disease, additional complexity factors should also be evaluated:
- Invasiveness and bleeding risk
- Drugs to be administered
- Level of consciousness, such as the use of sedation or general anesthesia
- Risk of aspiration, asphyxiation, or infection
- Impact on associated structures
- Reversibility or irreversibility of the planned treatment
- Duration and stress of the procedure
As can be seen from the list of factors that influence treatment outcomes, the presence of systemic disease is only a part of the equation. However, the focus of this activity is on dental management recommendations for patients with systemic diseases.
Systemic Disease Requiring Modifications for Invasive Procedures
Most dental therapies, such as restorations, periodontal treatment, the use of local anesthetics with epinephrine, and single-tooth extractions, are considered minimally invasive procedures. Thus, complications are usually minimal and centered around peri- and postoperative risk of infection, bleeding, drug interactions/complications, and the patient's ability to tolerate the planned procedures. If more invasive procedures are planned, such as removal of impacted wisdom teeth, extraction of multiple teeth, or osseous surgery, an additional risk assessment using the American College of Cardiology/American Heart Association (ACC/AHA) perioperative cardiovascular management guidelines for noncardiac surgery [15] may be helpful.
Hypertension: Dental visits may be anxiety-provoking for many patients. Assessment of a patient's blood pressure at dental visits is the standard of care. Guidelines exist for managing patients with elevated blood pressure readings, and stress-reduction protocols are universally recommended. Although guidance is based on possible risks associated with increased blood pressure readings, and recommendations include deferring dental treatment in the presence of blood pressure readings above 180/110 mm Hg when cardiovascular symptoms are present, there is limited evidence to support this guidance.[15] An additional consideration is the potential for an adverse reaction, such as significantly elevated blood pressure, when a dentist administers local anesthetics containing epinephrine to a patient who takes a nonselective beta-blocker medication.[16] Therefore, the most common recommendation is to limit the use of epinephrine-containing local anesthetics to 0.04 mg of epinephrine (equivalent to 2 cartridges of 1:100,000 epinephrine to local anesthetic) in patients taking a nonselective beta-blocker medication to avoid this potential life-threatening crisis. However, at least one observational study has noted decreases in blood pressure secondary to other blood pressure medications, such as calcium channel blockers, angiotensin II receptor antagonists, and alpha-blockers, when local anesthetics are used in dentistry.[17]
Endocarditis: As the oral cavity has an extensive microbiome and bleeding is occasionally associated with dental treatments, bacteremias may be related to specific dental procedures. Because of the high mortality and morbidity associated with infective endocarditis, patients with a history of infective endocarditis or other at-risk cardiac conditions are recommended by the AHA to receive antibiotic prophylaxis before specific dental procedures.[18]
A recent systematic review and meta-analysis of case-control, crossover, and cohort studies [19] indicates that antibiotic prophylaxis is associated with a lower risk of developing infective endocarditis after dental procedures.[20] The AHA currently does not recommend the use of antibiotic prophylaxis in patients at low- and medium-risk of developing infective endocarditis after invasive dental procedures.
Neutropenia: Patients may have an underlying primary neutropenia, such as autoimmune or cyclic neutropenia, or secondary neutropenia resulting from medications, cancers, or infections. The risk of postoperative infection is common to many invasive procedures. However, the highly vascular nature and proximity of the oral cavity to many vital structures, such as the airway, central nervous system, and carotid arteries, means that infections that track through head and neck tissue spaces can become life-threatening. The prevalence of immunosuppression in the community is increasing for several reasons, including an aging population and the growing use of immunomodulatory medications for disease management. Immunosuppression is thought to occur in 6.6% of the adult population in the United States.[21] Although evidence-based literature is limited, current guidance based on expert opinion suggests that patients with an absolute neutrophil count of less than 500/μL, and in some cases less than 1000/μL, may warrant antibiotic prophylaxis for invasive dental treatments. This decision depends on multiple factors, including the underlying cause of the neutropenia and its expected duration.
Independent of neutropenia, lymphopenic patients with CD4+ T-lymphocyte cell counts of 300 to 500 cells/mm³ or those with counts less than 200 cells/mm³ are at risk of opportunistic infections from many organisms in the oral microbiome, as well as from latent viral infections. Candida species infection (C albicans or C glabrata) is the most common oral opportunistic infection. Still, other organisms, including bacteria and viruses, are also capable of infecting the oral cavity. Although guidelines exist for the prevention of common opportunistic infections in individuals with HIV infection, routine prophylaxis for oral, oropharyngeal, and esophageal fungal infections is not recommended. Instead, to avoid the development of drug-resistant organisms, treatment of any fungal infection is recommended on an as-needed basis.[Clinicalinfo.HIV.gov. Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents With HIV]
Additionally, many disorders place patients at an increased risk of infection, including autoimmune conditions, diabetes, and end-stage renal disease. In the presence of existing oral infections, such as dental abscesses, the potential for hematologic seeding of infection to distant prostheses should be considered. Current joint guidance from the American Dental Association and the American Academy of Orthopedic Clinicians [22] suggests not to routinely prescribe antibiotics on a prophylactic basis for patients with prosthetic joints. For other forms of prosthetic implants, such as ocular lenses, breast implants, and dental implants, as well as prostheses, such as orthopedic plates or screws, pacemakers, and implantable cardioverter devices, prophylactic antibiotics are not recommended unless the dental procedure is performed within 6 months of implant placement. In this case, consideration of using antibiotics is deemed reasonable. However, in the presence of a dental infection at the site of the dental procedure, patients with synthetic arterial or cardiac grafts or stents, or patients with a central intravenous catheter or left ventricular assist device (LVAD) may be treated with antibiotic prophylaxis. The evidence for this is empirical, rather than based on clinical trials.[23] Many medical centers consider LVADs to be similar to prosthetic heart valves, highlighting the importance of consultation between the cardiology team and the oral healthcare team.[24] Some patients with second-generation LVADs may also develop an acquired von Willebrand disease, secondary to shear forces impacting and damaging the von Willebrand factor protein.
Coagulopathy: Primary coagulopathies, such as von Willebrand disease and autoimmune thrombocytopenia, or secondary coagulopathies, including liver disease and the effects of certain medications, can also pose a challenge to dentists. Bleeding is a common consequence of dental procedures and is typically managed with local measures such as the use of pressure, primary closure, and local hemostatic agents. The presence of liver disease, such as secondary to cirrhosis or hepatitis, or thrombocytopenia, including secondary to malignancy or autoimmune disease, can warrant a more comprehensive understanding of the severity of their condition and their ability to clot. Prophylactic measures may be necessary if bleeding is anticipated.
Common diagnostic tests used to assess perioperative bleeding risk include measures of bleeding/clotting (platelet count >50,000/µL), liver function tests (aspartate aminotransferase [ALT], alanine aminotransferase [AST], albumin, and bilirubin), and international normalized ratio (INR). Understanding the underlying cause of the coagulopathy is crucial for accurately evaluating the risk and selecting the appropriate blood test. For example, a patient taking warfarin may be successfully treated for a simple dental extraction with an INR value of around 2.5. However, a patient not taking warfarin with similar INR is likely to hemorrhage during and after an invasive dental procedure. Test values for safely extracting a tooth are considered to be represented by platelet counts of greater than 50,000/µL, INR of greater than 0.8 and less than 1.2 in a nonanticoagulated patient (or up to 3.5 in a patient taking coumadin), AST levels less than 37 U/L, ALT levels less than 41 U/L, and total bilirubin less than 2 mg/dL.
Cancers (solid tumors or hematological): The treatment of various cancers involves assessing and removing potential foci of infection before initiating therapy, including examination of the oral cavity. Teeth that have a poor prognosis or are at risk of developing a disease (pulpal or periodontal) should be treated either endodontically, periodontally, or by extraction before cancer therapy. Cancer therapy may involve chemotherapy, which can alter the immune system and increase the risk of infection. Additionally, it may lead to dry mouth, thereby increasing the risk of developing dental caries in the future.
Chemotherapy can induce oral mucositis, which is one of the most common adverse effects and may have a significant impact on the number of days spent in the inpatient setting.[25] Cancer treatment may also include radiation therapy. Radiation therapy for head and neck cancers may be intensity-modulated radiation therapy (IMRT) or intensity-modulated proton beam therapy (IMPT). Although quality of life outcomes are better with IMPT versus IMRT for the treatment of oropharyngeal cancers,[26] research is ongoing to compare rates of late-onset toxicity between IMRT and IMPT, including xerostomia, in patients with oropharyngeal cancer.[27] Suppose the radiation therapy is to the head and neck region. In that case, there is a risk of the patient developing osteoradionecrosis in the future when doses exceed 60 Gray and invasive dental procedures are performed. The risk of osteoradionecrosis is higher for the mandible than the maxilla, and if dental extractions are performed less than 7 days before the initiation of radiation.[28] Advances in three-dimensional radiation delivery to the head and neck have helped decrease the likelihood of patients developing osteoradionecrosis . One study comparing IMRT and IMPT showed a reduced rate of osteoradionecrosis of the jaw with IMPT, likely because of the reduction of excess irradiation to the mandible.[29] Other retrospective research showed that the use of epinephrine-free local anesthesia and conservative surgical techniques during dental extraction reduced the risk of osteoradionecrosis in this at-risk population.[30]
Bone marrow transplantation (BMT) is a standard treatment modality for various hematological malignancies. Whether BMT is autologous or allogeneic, induction therapy increases the patient's risk of de novo infection or reactivation of existing organisms, such as herpesviruses, and of developing oral mucositis. A thorough oral and dental evaluation is recommended both before and after treatment.[31] Additionally, post-BMT monitoring of the oral cavity for the development of graft-versus-host disease (GVHD) with allogeneic BMT is recommended, as well as assistance in managing common post-BMT oral cavity sensory disturbances or oral mucositis. Common manifestations of acute GVHD may include nonspecific mucositis, presenting as ulcerations or erythema of keratinized or nonkeratinized mucosa, or the lips. Onset of acute oral GVHD is typically 2 to 4 weeks post-BMT, but can present up to 6 months post-BMT.[32] Manifestations of chronic oral GVHD typically occur between 6 months and 2 years post-BMT. The classic presentation of chronic oral GVHD has lichenoid features, including atrophy, erythema, white striae with a reticular pattern, ulcerations, pseudomembrane, and mucocele formation. In addition, major salivary glands can be involved, resulting in xerostomia and hyposalivation, with associated symptoms and an increased risk of active caries. Furthermore, sclerosis of the skin and perioral tissues can occur, resulting in trismus and reduced oral opening, which makes the management of resultant caries and other oral diseases more difficult. Secondary malignancy surveillance is also an essential part of post-BMT oral care. Surveillance is recommended at least every 6 to 12 months post-BMT.
Both acute and chronic GVHD are often managed as part of systemic care, as they frequently affect multiple organs, including the skin, gastrointestinal tract, eyes, liver, and lungs. However, oral symptoms are often particularly evident, which can be managed with topical agents, such as steroids, lubricants, and emollients.
Post-cancer therapy, patients may be prescribed various types of immune-modulating medications, increasing the risk of infection in the oral cavity. Some patients, particularly those with breast cancer or prostate cancer, may be prescribed bisphosphonate medications. These medications are used to decrease the risk of bone metastasis associated with the primary cancer diagnosis. Unfortunately, their use has been associated with an increased risk of developing medication-related osteonecrosis of the jaw (MRONJ). MRONJ is defined by the Multinational Association of Supportive Care in Cancer (MASCC) as follows: (1) current or previous treatment with a bone-modifying agent or angiogenic inhibitor; (2) exposed bone or bone that can be probed through an intraoral or extraoral fistula in the maxillofacial region and that has persisted for longer than 8 weeks; and (3) no history of radiation therapy to the jaws or metastatic disease to the jaws. The risk of developing MRONJ is associated with the duration and potency of drug exposure (intravenous > oral route and zoledronate > risedronate > ibandronate > alendronate). Additionally, trauma to the jaw or gingiva, such as tooth extractions or bone biopsy procedures, increases this risk. Risk further increases with the age of the patient, the presence of periodontal disease or local infection, tobacco use, or corticosteroid use. Other anti-bone resorption medications beyond bisphosphonates have been implicated in the development of MRONJ, including denosumab, bevacizumab, sunitinib, everolimus, temsirolimus, and sorafenib.[33]
Medications: Medications prescribed by dentists can cause adverse effects due to hypersensitivity or drug-drug interactions. Clinical examples relevant to dentists include known allergies to medications or risks for severe dermatologic reactions associated with carbamazepine use, as well as the presence of HLA-B*1502 and possibly HLA*3101 alleles. Carbamazepine is known to reduce the effectiveness of some anti-retroviral drugs, particularly indinavir (Crixivan), atazanavir (Reyataz), dolutegravir (Tivicay), and tenofovir (Viread). Furthermore, ritonavir has been shown to increase the plasma concentration of carbamazepine by inhibiting the CYP3A4 enzyme, which is responsible for metabolizing carbamazepine.
When prescribing nonsteroidal anti-inflammatory drugs (NSAIDs) for medium- or long-term management, the presence of kidney dysfunction or gastric ulceration should be assessed. Furthermore, long-term NSAID use has been associated with the development of lichenoid mucositis and may reduce the effectiveness of antihypertensive medications. Liver function should be evaluated before prescribing or recommending acetaminophen, NSAIDs, azithromycin, erythromycin, or carbamazepine. Clarithromycin should be avoided in patients taking calcium channel blockers, those with poor kidney function,[34] or those with a cardiac arrhythmia.
Skeletal muscle relaxants may be prescribed to help manage temporomandibular disorders. Assessment of the patient's postural stability, gait stability, and potential risks associated with falls should be conducted, especially in older individuals. Similar considerations apply when prescribing sedative medications.
Calcium channel blocker drugs have also been associated with gingival overgrowth.[35] Dry mouth is a common side effect of many antihypertensive medications, as well as multiple medications in general, which increases the risk of dental caries and other oral disorders, such as trauma and oral candidiasis. Some antihypertensive drugs, such as angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, beta-blockers, and direct vasodilators, have been linked to the development of oral lichenoid lesions or lichenoid mucositis.[36]
Other Issues
Current Challenges and Potential Solutions
Many barriers exist that hinder information sharing, particularly the separation of electronic health records for medicine and dentistry. A unified patient health record may be an initial step towards easier information sharing and gathering for medical and dental care teams. Another barrier to information sharing is the patient's limited understanding of the integrated nature of oral health and systemic health, including the importance and relevance of general health information to the dental care team. Patients may wonder why a dentist needs to know about general health conditions, as it may not be readily apparent that systemic conditions can impact oral health. A greater understanding and education of the importance of information sharing with the dental care team may help decrease inadvertent withholding of relevant health information. At the professional level, increased interprofessional education during professional training programs can help reduce barriers to sharing information between care teams and reinforce the importance of the bidirectional relationship between oral and overall systemic health. Further enhancement of medical and dental rotations for trainees may help expand the clinical understanding of some of the concepts discussed in this activity. Finally, a continuation and expansion of interdisciplinary group efforts in producing professional guidelines for patient care that incorporate interprofessional collaboration and understanding, to help develop aligned and helpful guidance for both medical and dental care teams, thereby minimizing confusion and enhancing patient outcomes.
Examples of conditions where guidelines exist for dentists treating patients with medical complexities include:
- Infective endocarditis and antibiotic prophylaxis guidelines (American Heart Association, 2021).[37]
- Dental Management and Follow-Up Recommendations Based on Blood Pressure (Little and Falace, 10th Edition, Table 3.5).
- Prosthetic joint replacement (ADA Council for Scientific Affairs).[22]
- Diabetes and Periodontal Disease Consensus Report and Guidelines from the International Diabetes Federation and the European Federation of Periodontology.[38]
- Diagnostic Criteria for Temporomandibular Disorders (DC/TMD) and Recommendations.[39]
- American Association of Oral and Maxillofacial Surgeons' (AAOMS) Position Paper on MRONJ.[40]
- Obstructive Sleep Apnea (2015 Clinical Practice Guidelines, Dental Sleep Medicine).[41]
Enhancing Healthcare Team Outcomes
In summary, successful management of dental patients relies on thorough assessment, accurate diagnosis, and the implementation of preventive, personalized treatments that consider individual risks, physical status, medical conditions, and current medications. As patients live longer with more chronic diseases, dental care increasingly requires a solid understanding of medicine, pharmacology, and up-to-date clinical standards.
Effective collaboration between medical and dental providers is essential to ensure safe, comprehensive care and optimal oral health. This collaboration can be strengthened through enhanced communication between clinics, co-location of services within community health centers, and greater access to dental consultations in hospital inpatient and outpatient settings.
References
Vacaru RP, Didilescu AC, Sfeatcu R, Tănase M, Munteanu A, Miricescu D, Kaman WE, Brand HS. The Effect of Dental Treatments in Caries Management on Stress and Salivary Protein Levels. Journal of clinical medicine. 2022 Jul 27:11(15):. doi: 10.3390/jcm11154350. Epub 2022 Jul 27 [PubMed PMID: 35893440]
Reuter NG, Westgate PM, Ingram M, Miller CS. Death related to dental treatment: a systematic review. Oral surgery, oral medicine, oral pathology and oral radiology. 2017 Feb:123(2):194-204.e10. doi: 10.1016/j.oooo.2016.10.015. Epub 2016 Nov 2 [PubMed PMID: 27989710]
Level 1 (high-level) evidenceSatcher DS. Surgeon General's report on oral health. Public health reports (Washington, D.C. : 1974). 2000 Sep-Oct:115(5):489-90 [PubMed PMID: 11236021]
Lamster IB. The 2021 WHO Resolution on Oral Health. International dental journal. 2021 Aug:71(4):279-280. doi: 10.1016/j.identj.2021.06.003. Epub 2021 Jul 10 [PubMed PMID: 34256923]
Satcher D, Nottingham JH. Revisiting Oral Health in America: A Report of the Surgeon General. American journal of public health. 2017 May:107(S1):S32-S33. doi: 10.2105/AJPH.2017.303687. Epub [PubMed PMID: 28661821]
Foroughi M, Torabinejad M, Angelov N, Ojcius DM, Parang K, Ravnan M, Lam J. Bridging oral and systemic health: exploring pathogenesis, biomarkers, and diagnostic innovations in periodontal disease. Infection. 2025 May 26:():. doi: 10.1007/s15010-025-02568-y. Epub 2025 May 26 [PubMed PMID: 40418274]
Genco RJ, Sanz M. Clinical and public health implications of periodontal and systemic diseases: An overview. Periodontology 2000. 2020 Jun:83(1):7-13. doi: 10.1111/prd.12344. Epub [PubMed PMID: 32385880]
Level 3 (low-level) evidencePfister DG, Spencer S, Adelstein D, Adkins D, Anzai Y, Brizel DM, Bruce JY, Busse PM, Caudell JJ, Cmelak AJ, Colevas AD, Eisele DW, Fenton M, Foote RL, Galloway T, Gillison ML, Haddad RI, Hicks WL, Hitchcock YJ, Jimeno A, Leizman D, Maghami E, Mell LK, Mittal BB, Pinto HA, Ridge JA, Rocco JW, Rodriguez CP, Shah JP, Weber RS, Weinstein G, Witek M, Worden F, Yom SS, Zhen W, Burns JL, Darlow SD. Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : JNCCN. 2020 Jul:18(7):873-898. doi: 10.6004/jnccn.2020.0031. Epub [PubMed PMID: 32634781]
Level 1 (high-level) evidenceMirfendereski P, France K. Patient Receiving Hematopoietic Stem Cell Transplantation Reports for Dental Clearance. Dental clinics of North America. 2023 Jul:67(3):447-451. doi: 10.1016/j.cden.2023.02.016. Epub 2023 Apr 7 [PubMed PMID: 37244712]
Cotti E, Cairo F, Bassareo PP, Fonzar F, Venturi M, Landi L, Parolari A, Franco V, Fabiani C, Barili F, Di Lenarda A, Gulizia M, Borzi M, Campus G, Musumeci F, Mercuro G. Perioperative dental screening and treatment in patients undergoing cardiothoracic surgery and interventional cardiovascular procedures. A consensus report based on RAND/UCLA methodology. International endodontic journal. 2020 Feb:53(2):186-199. doi: 10.1111/iej.13166. Epub 2019 Dec 20 [PubMed PMID: 31162683]
Level 3 (low-level) evidencePotter C, Ritson Z, Walton G, Coats L, Irvine T, Ohlsen-Turner K. The heart of it: dental care and cardiothoracic surgery. British dental journal. 2024 Jul:237(1):33-39. doi: 10.1038/s41415-024-7558-6. Epub 2024 Jul 12 [PubMed PMID: 38997368]
Fernández-Feijoo J, Garea-Gorís R, Fernández-Varela M, Tomás-Carmona I, Diniz-Freitas M, Limeres-Posse J. Prevalence of systemic diseases among patients requesting dental consultation in the public and private systems. Medicina oral, patologia oral y cirugia bucal. 2012 Jan 1:17(1):e89-93 [PubMed PMID: 22157672]
Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. Journal of chronic diseases. 1987:40(5):373-83 [PubMed PMID: 3558716]
Level 1 (high-level) evidenceD'Hoore W, Sicotte C, Tilquin C. Risk adjustment in outcome assessment: the Charlson comorbidity index. Methods of information in medicine. 1993 Nov:32(5):382-7 [PubMed PMID: 8295545]
Nath S, Jiang T, Barrow J, Simon L. Treatment deferral for elevated blood pressure at a dental school clinic. Journal of dental education. 2024 Jan:88(1):51-55. doi: 10.1002/jdd.13369. Epub 2023 Sep 19 [PubMed PMID: 37727061]
Zhang C, Banting DW, Gelb AW, Hamilton JT. Effect of beta-adrenoreceptor blockade with nadolol on the duration of local anesthesia. Journal of the American Dental Association (1939). 1999 Dec:130(12):1773-80 [PubMed PMID: 10599182]
Ouchi K, Jinnouchi A. Calcium channel blockers, angiotensin II receptor antagonists and alpha-blockers accentuate blood pressure reducing caused by dental local anesthesia. Clinical oral investigations. 2021 Aug:25(8):4879-4886. doi: 10.1007/s00784-021-03795-x. Epub 2021 Jan 28 [PubMed PMID: 33506427]
Thornhill MH, Dayer M, Lockhart PB, McGurk M, Shanson D, Prendergast B, Chambers JB. A change in the NICE guidelines on antibiotic prophylaxis. British dental journal. 2016 Aug 12:221(3):112-4. doi: 10.1038/sj.bdj.2016.554. Epub [PubMed PMID: 27514339]
Sperotto F, France K, Gobbo M, Bindakhil M, Pimolbutr K, Holmes H, Monteiro L, Graham L, Hong CHL, Sollecito TP, Lodi G, Lockhart PB, Thornhill M, Diz Dios P, Turati F, Edefonti V. Antibiotic Prophylaxis and Infective Endocarditis Incidence Following Invasive Dental Procedures: A Systematic Review and Meta-Analysis. JAMA cardiology. 2024 Jul 1:9(7):599-610. doi: 10.1001/jamacardio.2024.0873. Epub [PubMed PMID: 38581643]
Level 1 (high-level) evidenceThornhill MH, Crum A, Campbell R, Stone T, Lee EC, Bradburn M, Fibisan V, Dayer M, Prendergast BD, Lockhart P, Baddour L, Nicoll J. Temporal association between invasive procedures and infective endocarditis. Heart (British Cardiac Society). 2023 Jan 11:109(3):223-231. doi: 10.1136/heartjnl-2022-321519. Epub 2023 Jan 11 [PubMed PMID: 36137742]
Martinson ML, Lapham J. Prevalence of Immunosuppression Among US Adults. JAMA. 2024 Mar 12:331(10):880-882. doi: 10.1001/jama.2023.28019. Epub [PubMed PMID: 38358771]
Sollecito TP, Abt E, Lockhart PB, Truelove E, Paumier TM, Tracy SL, Tampi M, Beltrán-Aguilar ED, Frantsve-Hawley J. The use of prophylactic antibiotics prior to dental procedures in patients with prosthetic joints: Evidence-based clinical practice guideline for dental practitioners--a report of the American Dental Association Council on Scientific Affairs. Journal of the American Dental Association (1939). 2015 Jan:146(1):11-16.e8. doi: 10.1016/j.adaj.2014.11.012. Epub 2014 Dec 18 [PubMed PMID: 25569493]
Level 1 (high-level) evidenceHong CH, Allred R, Napenas JJ, Brennan MT, Baddour LM, Lockhart PB. Antibiotic prophylaxis for dental procedures to prevent indwelling venous catheter-related infections. The American journal of medicine. 2010 Dec:123(12):1128-33. doi: 10.1016/j.amjmed.2010.08.009. Epub 2010 Oct 19 [PubMed PMID: 20961528]
Kim YH, Pavone J, Wasmuht-Perroud VAB, Frare RW, Baker PR. The left ventricular assist device: a literature review and guidelines for dental care. General dentistry. 2024 Jan-Feb:72(1):34-42 [PubMed PMID: 38117639]
Yuwanati M, Gondivkar S, Sarode SC, Gadbail A, Desai A, Mhaske S, Pathak SK, N Khatib M. Oral health-related quality of life in oral cancer patients: systematic review and meta-analysis. Future oncology (London, England). 2021 Mar:17(8):979-990. doi: 10.2217/fon-2020-0881. Epub 2021 Feb 5 [PubMed PMID: 33541115]
Level 1 (high-level) evidenceSharma S, Zhou O, Thompson R, Gabriel P, Chalian A, Rassekh C, Weinstein GS, O'Malley BW Jr, Aggarwal C, Bauml J, Cohen RB, Lukens JN, Swisher-McClure S, Ghiam AF, Ahn PH, Lin A. Quality of Life of Postoperative Photon versus Proton Radiation Therapy for Oropharynx Cancer. International journal of particle therapy. 2018 Fall:5(2):11-17. doi: 10.14338/IJPT-18-00032.1. Epub 2018 Nov 30 [PubMed PMID: 31773030]
Level 2 (mid-level) evidenceGunn GB, Blanchard P, Garden AS, Zhu XR, Fuller CD, Mohamed AS, Morrison WH, Phan J, Beadle BM, Skinner HD, Sturgis EM, Kies MS, Hutcheson KA, Rosenthal DI, Mohan R, Gillin MT, Frank SJ. Clinical Outcomes and Patterns of Disease Recurrence After Intensity Modulated Proton Therapy for Oropharyngeal Squamous Carcinoma. International journal of radiation oncology, biology, physics. 2016 May 1:95(1):360-367. doi: 10.1016/j.ijrobp.2016.02.021. Epub 2016 Feb 12 [PubMed PMID: 27084653]
Level 2 (mid-level) evidenceLee J, Hueniken K, Cuddy K, Pu J, El Maghrabi A, Hope A, Hosni A, Glogauer M, Watson E. Dental Extractions Before Radiation Therapy and the Risk of Osteoradionecrosis in Patients With Head and Neck Cancer. JAMA otolaryngology-- head & neck surgery. 2023 Dec 1:149(12):1130-1139. doi: 10.1001/jamaoto.2023.3429. Epub [PubMed PMID: 37856115]
Zhang W, Zhang X, Yang P, Blanchard P, Garden AS, Gunn B, Fuller CD, Chambers M, Hutcheson KA, Ye R, Lai SY, Radwan MAS, Zhu XR, Frank SJ. Intensity-modulated proton therapy and osteoradionecrosis in oropharyngeal cancer. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2017 Jun:123(3):401-405. doi: 10.1016/j.radonc.2017.05.006. Epub 2017 May 23 [PubMed PMID: 28549794]
Maxymiw WG, Wood RE, Liu FF. Postradiation dental extractions without hyperbaric oxygen. Oral surgery, oral medicine, and oral pathology. 1991 Sep:72(3):270-4 [PubMed PMID: 1923410]
Elad S, Cheng KKF, Lalla RV, Yarom N, Hong C, Logan RM, Bowen J, Gibson R, Saunders DP, Zadik Y, Ariyawardana A, Correa ME, Ranna V, Bossi P, Mucositis Guidelines Leadership Group of the Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology (MASCC/ISOO). MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer. 2020 Oct 1:126(19):4423-4431. doi: 10.1002/cncr.33100. Epub 2020 Jul 28 [PubMed PMID: 32786044]
Level 1 (high-level) evidenceIon D, Stevenson K, Woo SB, Ho VT, Soiffer R, Antin JH, Treister NS. Characterization of oral involvement in acute graft-versus-host disease. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2014 Nov:20(11):1717-21. doi: 10.1016/j.bbmt.2014.06.031. Epub 2014 Jun 27 [PubMed PMID: 24979731]
Ahdi HS, Wichelmann TA, Pandravada S, Ehrenpreis ED. Medication-induced osteonecrosis of the jaw: a review of cases from the Food and Drug Administration Adverse Event Reporting System (FAERS). BMC pharmacology & toxicology. 2023 Mar 6:24(1):15. doi: 10.1186/s40360-023-00657-y. Epub 2023 Mar 6 [PubMed PMID: 36879299]
Level 3 (low-level) evidenceGandhi S, Fleet JL, Bailey DG, McArthur E, Wald R, Rehman F, Garg AX. Calcium-channel blocker-clarithromycin drug interactions and acute kidney injury. JAMA. 2013 Dec 18:310(23):2544-53. doi: 10.1001/jama.2013.282426. Epub [PubMed PMID: 24346990]
Level 2 (mid-level) evidenceLivada R, Shiloah J. Calcium channel blocker-induced gingival enlargement. Journal of human hypertension. 2014 Jan:28(1):10-4. doi: 10.1038/jhh.2013.47. Epub 2013 Jun 6 [PubMed PMID: 23739159]
Kaomongkolgit R. Oral lichenoid drug reaction associated with antihypertensive and hypoglycemic drugs. Journal of drugs in dermatology : JDD. 2010 Jan:9(1):73-5 [PubMed PMID: 20120430]
Baddour LM, Wilson WR, Bayer AS, Fowler VG Jr, Tleyjeh IM, Rybak MJ, Barsic B, Lockhart PB, Gewitz MH, Levison ME, Bolger AF, Steckelberg JM, Baltimore RS, Fink AM, O'Gara P, Taubert KA, American Heart Association Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease of the Council on Cardiovascular Disease in the Young, Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and Stroke Council. Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Scientific Statement for Healthcare Professionals From the American Heart Association. Circulation. 2015 Oct 13:132(15):1435-86. doi: 10.1161/CIR.0000000000000296. Epub 2015 Sep 15 [PubMed PMID: 26373316]
Sanz M, Ceriello A, Buysschaert M, Chapple I, Demmer RT, Graziani F, Herrera D, Jepsen S, Lione L, Madianos P, Mathur M, Montanya E, Shapira L, Tonetti M, Vegh D. Scientific evidence on the links between periodontal diseases and diabetes: Consensus report and guidelines of the joint workshop on periodontal diseases and diabetes by the International Diabetes Federation and the European Federation of Periodontology. Journal of clinical periodontology. 2018 Feb:45(2):138-149. doi: 10.1111/jcpe.12808. Epub 2017 Dec 26 [PubMed PMID: 29280174]
Level 3 (low-level) evidenceSchiffman E,Ohrbach R,Truelove E,Look J,Anderson G,Goulet JP,List T,Svensson P,Gonzalez Y,Lobbezoo F,Michelotti A,Brooks SL,Ceusters W,Drangsholt M,Ettlin D,Gaul C,Goldberg LJ,Haythornthwaite JA,Hollender L,Jensen R,John MT,De Laat A,de Leeuw R,Maixner W,van der Meulen M,Murray GM,Nixdorf DR,Palla S,Petersson A,Pionchon P,Smith B,Visscher CM,Zakrzewska J,Dworkin SF, Diagnostic Criteria for Temporomandibular Disorders (DC/TMD) for Clinical and Research Applications: recommendations of the International RDC/TMD Consortium Network* and Orofacial Pain Special Interest Group†. Journal of oral & facial pain and headache. 2014 Winter [PubMed PMID: 24482784]
Ruggiero SL, Dodson TB, Aghaloo T, Carlson ER, Ward BB, Kademani D. American Association of Oral and Maxillofacial Surgeons' Position Paper on Medication-Related Osteonecrosis of the Jaws-2022 Update. Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons. 2022 May:80(5):920-943. doi: 10.1016/j.joms.2022.02.008. Epub 2022 Feb 21 [PubMed PMID: 35300956]
Ramar K, Dort LC, Katz SG, Lettieri CJ, Harrod CG, Thomas SM, Chervin RD. Clinical Practice Guideline for the Treatment of Obstructive Sleep Apnea and Snoring with Oral Appliance Therapy: An Update for 2015. Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine. 2015 Jul 15:11(7):773-827. doi: 10.5664/jcsm.4858. Epub 2015 Jul 15 [PubMed PMID: 26094920]
Level 1 (high-level) evidence